Canopy Growth Corporation (CGC)
NASDAQ: CGC · Real-Time Price · USD
0.6653
-0.0067 (-1.00%)
At close: Oct 22, 2026, 4:00 PM EDT
0.6652
-0.0001 (-0.02%)
Pre-market: Oct 23, 2026, 4:17 AM EDT
Canopy Growth Revenue
Canopy Growth had revenue of 81.17M CAD in the quarter ending June 30, 2026, with 12.52% growth. This brings the company's total for the last twelve months to 293.63M, up 6.81% year-over-year. In the fiscal year ending March 31, 2026, Canopy Growth had annual revenue of 284.60M with 5.80% growth.
Revenue (ttm)
293.63M CAD
Revenue Growth
+6.81%
P/S Ratio
1.37
Revenue / Employee
260,314 CAD
Employees
1,128
Market Cap
283.33M USD
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full Canopy Growth breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 284.60M | 15.61M | 5.80% |
| Mar 31, 2025 | 269.00M | -28.15M | -9.47% |
| Mar 31, 2024 | 297.15M | -36.11M | -10.83% |
| Mar 31, 2023 | 333.25M | -177.07M | -34.70% |
| Mar 31, 2022 | 510.32M | -36.33M | -6.65% |
| Mar 31, 2021 | 546.65M | 147.88M | 37.08% |
| Mar 31, 2020 | 398.77M | 172.43M | 76.18% |
| Mar 31, 2019 | 226.34M | 148.39M | 190.37% |
| Mar 31, 2018 | 77.95M | 38.05M | 95.38% |
| Mar 31, 2017 | 39.90M | 27.20M | 214.16% |
| Mar 31, 2016 | 12.70M | 10.33M | 435.60% |
| Mar 31, 2015 | 2.37M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 963.10M |
| Emergent BioSolutions | 770.20M |
| Aurora Cannabis | 221.16M |
| Kamada | 191.85M |
| Glass House Brands | 176.98M |
| Lifecore Biomedical | 129.46M |
| Anika Therapeutics | 120.65M |
| Aquestive Therapeutics | 54.09M |
CGC News
- 22 hours ago - Canopy Growth to Report Second Quarter Fiscal 2027 Financial Results on November 6, 2026 - Business Wire
- 4 days ago - Trump's Marijuana Order Is Stuck at the DEA. Here's What That Means for Canopy Growth. - The Motley Fool
- 6 days ago - Canopy Growth Proxy statement: Proxy filing - Filings
- 7 days ago - Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026? - The Motley Fool
- 8 days ago - Here's Why Canopy Growth Corporation (CGC) Fell More Than Broader Market - Nasdaq
- 9 days ago - Canopy Growth’s Smiths Falls received EU GMP certification - TheFly
- 9 days ago - Canopy Growth's Smiths Falls Facility Becomes Canada's Only EU GMP-Certified Site Combining Softgel Manufacturing With Primary Packaging of Softgels, Oral Liquids and Dried Cannabis Flower - Business Wire
- 12 days ago - Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool